Waltham, MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) is a scientific instrument maker and a world leader in serving science. The company is on a healthy growth trajectory of late andhas rallied 17.7% over the past three months, ahead of the S&P 500’s 3.2% gain. The stock has a market cap of $70.8 billion.
The company has also considerably outperformed the Zacks categorized Medical - Products sub-industry’s gain of 11.9%.
Notably, this Zacks Rank #2 (Buy) company’s estimate revision trend for the current year is favorable. In the last 60 days, four estimates have moved up with no revision in the opposite direction. The magnitude of estimate revision increased around 0.65% to $9.22 per share. The company delivered a four-quarter positive average earnings surprise of 2.3% and an earnings surprise of 2.97% in the last reported first quarter of 2017.
With strong growth prospects, Thermo Fisher is an attractive pick at present.
Thermo Fisher’s continuous efforts to drive growth inorganically through acquisition activities have been generating a lot of enthusiasm among investors. In May, the company had announced its agreement to acquire Netherlands-based Patheon N.V., a global provider of high-quality drug solutions to pharmaceutical and biopharma sectors.
Thermo Fisher expects to derive a lot of synergies through this buyout to help expand its biopharma offerings in Europe. The combination is anticipated to strengthen Thermo Fisher’s foothold in the Pharmaceutical and Biotech markets by adding highly complementary services to its portfolio.
Also the acquisition of FEI, which has already started generating synergies and contributing largely to the company’s analytical instruments portfolio, has in turn boosted market optimism about the stock.
The market is also upbeat about the company’s focus to gain traction in the high-potential emerging geographies. In China, Thermo Fisher has been delivering solid results in markets like biopharma, healthcare and environment. In order to meet the rising demand for clinical trials in South Korea, the company recently launched a BioPharma services unit. Significantly, Thermo Fisher is continuously working to cash in on the opportunities in BioPharma, healthcare and food safety markets of India.
Other Key Picks
Other top-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , Edwards Lifesciences Corp. (EW - Free Report) and Align Technology, Inc. (ALGN - Free Report) . While Mesa Laboratories and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Mesa Laboratories delivers a positive earnings surprise of 2.84% over the last four quarters. The stock added roughly 9.1% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock surged around 21.3% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock jumped nearly 32.1% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>